The announcement of the Phase 2 GALAXIES Lung-201 interim data presentation is a positive development for iTeos Therapeutics, likely boosting investor confidence and driving the stock price up. The presentation at a prestigious event like the ESMO Congress adds credibility and visibility to the company's research efforts.